Orili 150 mg (Tablet)
Unit Price: ৳ 170.00 (2 x 6: ৳ 2,040.00)
Strip Price: ৳ 1,020.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Elagolix sodium |
| Company | Square pharmaceuticals plc |
| Also available as |
Indications
- Management of moderate to severe pain
- Endometriosis
Pharmacology
- GnRH receptor antagonist
- Inhibits endogenous GnRH signaling
- Competitively binds to GnRH receptors
- Suppresses luteinizing hormone (LH)
- Suppresses follicle-stimulating hormone (FSH)
- Decreases blood concentrations of ovarian sex hormones
- Decreases estradiol concentrations
- Decreases progesterone concentrations
Dosage & Administration
- Pregnancy exclusion prior to treatment
- Start within 7 days from the onset of menses
- Initial treatment with 150 mg once daily for up to 24 months
- Initial treatment with 200 mg twice daily for up to 6 months
- Limited use in moderate to severe hepatic impairment
- Not established for children and adolescents
Interaction
- May potentiate P-gp substrates (e.g. digoxin)
- May potentiate CYP2C19 substrates (e.g. omeprazole)
- May antagonize CYP3A substrates
- Antagonizes oral midazolam
- Antagonizes rosuvastatin
- May be antagonized by CYP3A inducers
- Reduced efficacy with estrogen-containing contraceptives
- No known food interaction
Contraindications
- Pregnancy
- Known osteoporosis
- Severe hepatic impairment
- Concomitant use of strong OATP1B1 inhibitors (e.g. cyclosporine, gemfibrozil)
Side Effects
- Hot flushes
- Night sweats
- Headache
- Nausea
- Amenorrhea
- Arthralgia
- Mood changes
- Bone loss
- Insomnia
- Anxiety
- Elevated hepatic transaminase
Pregnancy & Lactation
- Insufficient human data
- Risk of major birth defects
- Risk of miscarriage
- Contraindicated in pregnant women
- Discontinue if pregnancy occurs
- Unknown presence in human milk
Precautions & Warnings
- Dose-dependent decreases in bone mineral density
- Reduced ability to recognize pregnancy
- Suicidal ideation and mood disorders
- Dose-dependent elevations in serum alanine aminotransferase
- Potential for reduced efficacy with estrogen-containing contraceptives
Use in Special Populations
- No dose adjustment in women with renal impairment
- No dosage adjustment in women with mild hepatic impairment
- Not established for patients less than 18 years of age
Overdose Effects
- Monitor signs or symptoms of adverse reactions
- Initiate appropriate symptomatic treatment
Therapeutic Class
- Gonadotropin-releasing hormone (GnRH) antagonist
Storage Conditions
- Cool and dry storage
- Protection from light and moisture
- Keep out of reach of children